WEDNESDAY, July 8, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT).
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for mitapivat, an oral pyruvate kinase (PK) activator, in sickle cell disease with a Priority Review.
For thousands of Nigerian families, the joy of welcoming a new born is often overshadowed by an invisible threat; Sickle Cell Disease (SCD). For many, the diagnosis marks the beginning of a lifelong journey of pain, resilience and hope.
PEORIA (25News Now) - The American Red Cross is encouraging blood donations from diverse backgrounds as World Sickle Cell Day and Juneteenth highlight the need for compatible blood for patients living with sickle cell disease.
NAIROBI, Kenya / KAMPALA, Uganda — African health leaders and partners today launched the Imara Sickle Cell Framework, a new regional initiative designed to help countries strengthen sickle cell disease care by translating policy priorities into practical, coordinated delivery within national health systems.
For E’Shon guy, frequent and spontaneous medical crises meant spending birthdays in the hospital, missing school regularly and needing emergency care more than two dozen times throughout his childhood.
One of Audrey Patricia Smith's early defining memories of sickle cell disease was in Myrtle Beach, South Carolina, in 1959, when she was 12 years old and visiting the ocean with family friends. Before then, Smith had not yet experienced a pain crisis.
Every year on June 19th, communities, healthcare providers, and policymaker
A patient with severe sickle cell disease (SCD) remained free of two key SCD symptoms — including painful vaso-occlusive crises — for more than a year after receiving a single dose of CS-206, Correctsequence Therapeutics‘ investigational gene-editing therapy, new data show.
Understanding Sickl